Navigation Links
Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis

- Anti-IL-2 receptor antibody significantly reduced the number of new or enlarged lesions compared to placebo; data to be submitted for presentation at upcoming medical meeting -

CAMBRIDGE, Mass. and FREMONT, Calif., March 12, 2007 /PRNewswire-FirstCall/ -- Biogen Idec, Inc. and PDL BioPharma, Inc. (PDL) announced today that the ongoing CHOICE trial, a Phase 2, randomized, double-blind, placebo-controlled trial of daclizumab, met its primary endpoint in relapsing multiple sclerosis (MS) patients being treated with interferon beta. Patients receiving daclizumab 2 mg/kg subcutaneously every 2 weeks showed a significant reduction in the number of new or enlarged gadolinium-contrast-enhancing lesions (Gd-CELs) at week 24.

Daclizumab is a humanized monoclonal antibody that targets the IL-2 receptor on activated T cells. Study results will be submitted for presentation at an upcoming medical meeting later this year. Based on a joint review of the 24-week data, the companies plan to initiate a Phase 2 monotherapy trial of daclizumab, and to advance the overall clinical development program in relapsing MS.

"We are very pleased to see positive results from the first randomized trial of daclizumab in patients with relapsing MS, and we look forward to advancing the clinical development program with our partner and acknowledged leader in the MS field, Biogen Idec," said Mark A. McCamish, M.D., Ph.D., chief medical officer, PDL BioPharma. "While the week 24 data set will be presented later this year, we are planning to move forward with additional development activities, most notably the initiation of the SELECT trial, which will study daclizumab as a single agent in patients with relapsing MS."

"We congratulate PDL on conducting a successful trial of daclizumab in MS," said Al Sandrock, M.D., Ph.D., senior vice president, neurology research and development, Biogen Idec. "Daclizumab represents an exciti
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
5. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
6. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
7. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
8. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
9. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
10. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
11. Ceragenix Announces Results from Phase IV Study of EpiCeram Meet All Primary and Secondary Endpoints

Post Your Comments:
(Date:11/25/2009)... , PRINCETON, N.J., Nov. 25 /PRNewswire-Fir...inical stage pharmaceutical company committed to d...rugs to treat viral infections, reported financial...009. At September 30, 2009 Pharmasset held $58.4 m...vestments. ,, Pipeline Update and 2009 Highli...
(Date:11/25/2009)... , WEST PALM BEACH, Fla., Nov. 25 /PRNewsw...ing impaired Americans, especially the 27 million ... may not be all that happy, says audiologist Cindy...HearUSA (Amex: EAR ), one of America,s largest he...ies have linked hearing loss to stress, frustratio...
(Date:11/25/2009)... , NEW YORK, Nov. 25 R...ch report is available in its catalogue: ,, Un...ecasts to 2015 ,, http://www.reportlinker.com...ysis-and-Forecasts-to-2015.html ,, United Stat... 2015 ,, Summary ,, This report is an esse...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13Powe Award supports research on how enzymes enable the pathogenicity of 2 human disease organisms 8853 1Powe Award supports research on how enzymes enable the pathogenicity of 2 human disease organisms 8853 2Photos 3A FDA Clears Hologic R2 28TM 29 DigitalNow 28TM 29 HD Software Application 49044 1Photos 3A FDA Clears Hologic R2 28TM 29 DigitalNow 28TM 29 HD Software Application 49044 2Photos 3A FDA Clears Hologic R2 28TM 29 DigitalNow 28TM 29 HD Software Application 49044 3A Growing Number of Brits Cross the Atlantic for Donor Egg IVF Treatment at Shady Grove Fertility Center 49039 1A Growing Number of Brits Cross the Atlantic for Donor Egg IVF Treatment at Shady Grove Fertility Center 49039 2A Growing Number of Brits Cross the Atlantic for Donor Egg IVF Treatment at Shady Grove Fertility Center 49039 3
...nter.org/globalhealth , WASHINGTON, Sept. 17 Ear... a reauthorization of the President,s,Emergency Pl...e at the end,of fiscal year 2008. The plan calls f...mmitment of $15 billion to $30 billion over the ne...w Wilson Center,s Global Health,Initiative and Env...
...ics,Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) tod...l studies, it plans to undertake a Phase 1 transde...hronic pain sufferers with a,sustained-release pai... all necessary documents for approval of the,trial...t clinical research,organization located at the Ro...
Other Medicine Technology:Director's Forum: PEPFAR and the Global AIDS Response 2Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial 2
(Date:11/26/2009)...ental (RTDental), a leading dental group practice ...ansion of its services to include LUMINEERS by a c... , Durham, NC (PRWEB) -- R...t Dr. Doug Macmillan, an experienced LUMINEERS D...training seminar. RTDental’s ability to ful...
(Date:11/26/2009)...P.A. is offering free nationwide confidential cons...l pills who have suffered a Deep Vein Thrombosis (...other related cardiac issues or had their Gallblad...-6405 or go to the firm’s website at http:/...luation form. , (PRWEB) N...
(Date:11/25/2009)...swire/ -- The Bartle Hall Convention Center will t...nic on Dec. 9-10, when Kansas City hosts the lates...d people. ,, "This free clinic event has the po... extend over two days instead of just one and be h...Wood, executive director of the Kansas City Free H...
(Date:11/25/2009)...SentinelleMedicalInc.,aleadingmanufacturerofMagnet...cientificInc.,aleadingproviderofsoftwareenablingte...ast4DAdvancedVisualizationsoftware. ,, Thisinno...entbasedmedicalimagingofferinginthemarket.CalgaryS...intaccess-requiringnosoftwaredownload,andrunsonany...
(Date:11/25/2009)...wswire/ -- Thanksgiving meals will be delivered to...ter Long Beach area thanks to Faith In Action/Volu...pendence at Home (IAH), a division of SCAN Health ...ave gathered hundreds of volunteers to deliver war...ach, Lakewood, Signal Hill, South Bay, South Los A...
Breaking Medicine News(10 mins):Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2
...s announced on Thursday that plans are afoot to co...nsider listing on the US bourses after 2002," Prat... said, adding it was a part of the business plan f...m the present capacity are already underway and wi...
...hs due to asthma can be prevented if the patients ...disease. According to WHO, around 150 million peop...people die due to the disease every year. Asthma i...on, and coughing. The Asian study sponsored by ...
...in anti AIDS therapy, complimentary and alternativ...positive patients, according to a new study. Among... use of complementary and alternative therapies, 6...ent issue of The journal AIDS Patient Care and STD...
...s asked its members to refrain from conducting sex... No support would be extended to practitioners cau...organisation should warn our members against aidin...oeticide and infanticide organised by the IMA, Tam...
...a say, may actually cause more diseases than what ... disease, including Lyme disease and Rocky Mountai...nth's Journal of Clinical Microbiology implicates ...lness known as trench fever. Scientists had tho...
...ave opined after an exhaustive study that the brai...men and women and studied their responses to diffe...ity led the study. The fact that some people rely ...earchers have found. In the study, Berns and hi...
Other Medicine News:
Quantum II
...tomated, high-volume blood screening instrument de...Before a blood donation can enter the blood supply... that might cause disease. This screening process ...s and many manual steps. The ABBOTT PRISM instrume...
...tion to Automate Deparaffinization, FISH Specimen ...ou can perform deparaffinization, pretreatment, hi...ns and routine slide washing with a single system....ysis protocols for fluorescence in situ hybridizat...
Vysis GenoSensor System
Medicine Products: